❖ ~175K new cases of Prostate cancer diagnosed annually in men
❖ 2/3rds of diagnosis is in men over the age of 65
❖ Prostate cancer is the leading cause of death for men over the age of 75
❖ 3.1M men living with prostate cancer currently in the US
❖ We believe ALT-100 as a therapeutic can reduce prostate cancer progression, metastases and lethality.
❖ Targeting NAMPT for use as a possible diagnostic and prognostic tool for detection of prostate cancer (PCa) risk and severity.
❖ Preclinical data suggests that NAMPT participates in tumor/host cross-talk to influence the microenvironment resulting in prostate cancer invasion and metastasis.
❖ Aqualung’s ALT-100 as a biologic therapeutic can reducing systemic inflammation and inhibiting activation of evolutionarily-conserved inflammatory cascades that drive Prostate cancer progression.
❖ ALT-100 will antagonize the switch to aggressive ADT-resistant disease and preventing lethal prostate cancer.
